The future of ibogaine therapy was a central topic at the 2025 Psychedelic Science conference, where it was endorsed by former Texas governor Rick Perry and others. Other states are following suit, but some advocates worry about possible exploitation of the plant medicine. The post 2025: The Year of Ibogaine Therapy first appeared on Lucid News. The post 2025: The Year of Ibogaine Therapy appeared first on Lucid News.| Lucid News
The first aceclidine-based eye drop to improve near vision in adults with presbyopia, which affects more than 100 million adults in the US alone, has been approved by the Food and Drug Administration (FDA) and will be available within three months.| New Atlas
Dr. Katie Abouzahr, Johnson & Johnson’s new head of late-stage immunology development, draws on her NHS clinical roots and 11 years at Boston Consulting Group to tackle drug R&D’s most complex challenges. Having recently stepped into the role about a month ago, she oversees a portfolio that includes the newly FDA-approved nipocalimab for myasthenia gravis,… The post J&J bets on nipocalimab and oral peptides in immunology appeared first on Drug Discovery and Development.| Drug Discovery and Development
And more biotech news brought to you by The Readout.| STAT
Alkermes’ investigational drug helped people with a type of narcolepsy stay awake during the day in a mid-stage trial.| STAT
Scalability is a common issue facing pharma leaders who have deployed Generative AI (GenAI) applications as a proof of concept (PoC). Many are dazzled by their promise of streamlining staid work processes. Agentic AI and other new GenAI technologies can make PoCs faster and easier to launch, advancing scalability as well as security and development… The post Scaling pharma AI PoCs to enterprise deployments: Blending new tech with old-school rigor appeared first on Drug Discovery and Develop...| Drug Discovery and Development
Quantum technologies are an exciting prospect for our future and naturally interdisciplinary in solving complex questions. Dr Stephanie Simmons, Founder and Chief Quantum Officer at Photonic, is at the forefront [...] Read More... The post <strong>Photonic Inc:</strong> Creating relevant, scalable, and distributed quantum computing appeared first on Research Outreach.| Research Outreach
Glycan (sugar)-binding lectin-type receptors on immune cells have the potential to serve as therapeutic targets. However, many of these receptors are not targeted because of a lack of suitable binding [...] Read More... The post Glycomimetic peptides as powerful anti-inflammatory treatments appeared first on Research Outreach.| Research Outreach
PubMiner AI aims to help researchers in the biomedical domain overcome the challenges in automatic knowledge extraction from large volumes of scientific publications. The post Advancing Automatic Knowledge Extraction with PubMiner AI appeared first on Ontotext.| Ontotext
Nella vulgata mediatica l'accento è sempre stato su "scoperto il gene della malattia X, cura in tre anni" (immensa bestialità). Stanley Cohe...| ilchimicoscettico.blogspot.com
